146 related articles for article (PubMed ID: 38806204)
21. Budesonide/Formoterol or Budesonide/Albuterol as Anti-Inflammatory Reliever Therapy for Asthma.
Lipworth B; Kuo CR; Stewart K; Chan R
J Allergy Clin Immunol Pract; 2024 Apr; 12(4):889-893. PubMed ID: 38346474
[TBL] [Abstract][Full Text] [Related]
22. [Asthma treatment in general practice].
Behrendt V; Hilberg O; Bakker V; Ulrik CS; Bjerring N; Løkke A
Ugeskr Laeger; 2022 Jan; 184(2):. PubMed ID: 35023469
[TBL] [Abstract][Full Text] [Related]
23. Availability of the combination of formoterol and budesonide in the United States of America.
Blango CM; O'Brien CD
Allergy Asthma Proc; 2008; 29(4):426. PubMed ID: 18702893
[No Abstract] [Full Text] [Related]
24. Budesonide/formoterol maintenance and reliever therapy in childhood asthma: Real-world effectiveness and economic assessment.
Yu Y; Cao W; Xiao Y; Li A; Huang H; Liu K; Hu L; Hou X; Xiang L; Wang X
Pediatr Pulmonol; 2023 Dec; 58(12):3406-3415. PubMed ID: 37818789
[TBL] [Abstract][Full Text] [Related]
25. Budesonide/formoterol as maintenance and reliever therapy compared to fixed-budesonide/formoterol plus albuterol reliever for pediatric asthma: A cost-utility analysis in Colombia.
Rodríguez-Martínez CE; Sossa-Briceño MP; Nino G
J Allergy Clin Immunol Pract; 2021 Oct; 9(10):3816-3818.e2. PubMed ID: 34102348
[No Abstract] [Full Text] [Related]
26. Insights from the AUSTRI study on reliever use before and after asthma exacerbations.
Busse W; Stempel D; Aggarwal B; Boucot I; Forth R; Raphiou I; Rabe KF; Reddel HK
J Allergy Clin Immunol Pract; 2022 Jul; 10(7):1916-1918.e2. PubMed ID: 35413473
[No Abstract] [Full Text] [Related]
27. Budesonide/formoterol maintenance and reliever therapy via Turbuhaler versus fixed-dose budesonide/formoterol plus terbutaline in patients with asthma: phase III study results.
Atienza T; Aquino T; Fernández M; Boonsawat W; Kawai M; Kudo T; Ekelund J; Ivanov S; Carlsson LG
Respirology; 2013 Feb; 18(2):354-63. PubMed ID: 23126237
[TBL] [Abstract][Full Text] [Related]
28. A breath of fresh AIR: reducing the carbon footprint of asthma.
Hatter L; Bruce P; Beasley R
J Med Econ; 2022; 25(1):700-702. PubMed ID: 35574735
[No Abstract] [Full Text] [Related]
29. Asthma control with ICS-formoterol reliever versus maintenance ICS and SABA reliever therapy: a post hoc analysis of two randomised controlled trials.
Hatter L; Houghton C; Bruce P; Holliday M; Eathorne A; Pavord I; Reddel HK; Hancox RJ; Braithwaite I; Oldfield K; Papi A; Weatherall M; Beasley R;
BMJ Open Respir Res; 2022 Aug; 9(1):. PubMed ID: 36007980
[TBL] [Abstract][Full Text] [Related]
30. A Practical Guide to Implementing SMART in Asthma Management.
Reddel HK; Bateman ED; Schatz M; Krishnan JA; Cloutier MM
J Allergy Clin Immunol Pract; 2022 Jan; 10(1S):S31-S38. PubMed ID: 34666208
[TBL] [Abstract][Full Text] [Related]
31. Implementing Antiinflammatory Reliever Strategies in Asthma: The Evolving Paradigm of Asthma Management.
Zaeh SE; Eakin MN; Chupp G
Chest; 2024 Feb; 165(2):250-252. PubMed ID: 38336438
[No Abstract] [Full Text] [Related]
32. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
33. The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of two randomised, controlled studies with comparisons to standard therapy.
Buhl R; Kuna P; Peters MJ; Andersson TL; Naya IP; Peterson S; Rabe KF
Respir Res; 2012 Jul; 13(1):59. PubMed ID: 22816878
[TBL] [Abstract][Full Text] [Related]
34. Long-acting beta agonists in asthma therapy.
Rissmiller RW; Larj MJ; Peters SP
Curr Allergy Asthma Rep; 2004 Mar; 4(2):91-2. PubMed ID: 14769255
[No Abstract] [Full Text] [Related]
35. [A PHASE III STUDY TO EVALUATE SAFETY AND EFFICACY OF FLUTICASONE/FORMOTEROL COMBINATION (FLUTIFORM
Katsunuma T; Kamata M; Ishikawa Y
Arerugi; 2020; 69(5):341-352. PubMed ID: 32684549
[TBL] [Abstract][Full Text] [Related]
36. Beginning to Address an Implementation Gap in Asthma: Clinicians' Views of Prescribing Reliever Budesonide-Formoterol Inhalers and SMART in the United States.
Krings JG; Sekhar TC; Chen V; Blake KV; Sumino K; James AS; Clover AK; Lenze EJ; Brownson RC; Castro M
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2767-2777. PubMed ID: 37245736
[TBL] [Abstract][Full Text] [Related]
37. Budesonide-formoterol reliever therapy in intermittent
Papi A; Braithwaite I; Ebmeier S; Hancox RJ; Harrison T; Holliday M; Houghton C; Morandi L; Oldfield K; Pavord ID; Reddel HK; Williams M; Weatherall M; Beasley R;
Eur Respir J; 2021 Feb; 57(2):. PubMed ID: 33060151
[No Abstract] [Full Text] [Related]
38. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children.
Cates CJ; Karner C
Cochrane Database Syst Rev; 2013 Apr; 2013(4):CD007313. PubMed ID: 23633340
[TBL] [Abstract][Full Text] [Related]
39. Fluticasone/formoterol association favors long-lasting decrease in bronchial reactivity to methacholine and weekly PEF variability.
Cortese S; Gatta A; Della Valle L; Mangifesta R; Di Giampaolo L; Cavallucci E; Petrarca C; Paganelli R; Di Gioacchino M
Int J Immunopathol Pharmacol; 2016 Dec; 29(4):769-774. PubMed ID: 27272161
[TBL] [Abstract][Full Text] [Related]
40. Additive effects of inhaled formoterol and budesonide in reducing asthma exacerbations.
Pauwels R
Allergy; 1998; 53(42 Suppl):20-3. PubMed ID: 9615842
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
